BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rhee H, Kim MJ, Park MS, Kim KA. Differentiation of early hepatocellular carcinoma from benign hepatocellular nodules on gadoxetic acid-enhanced MRI. Br J Radiol 2012;85:e837-44. [PMID: 22553295 DOI: 10.1259/bjr/13212920] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Li X, Li C, Wang R, Ren J, Yang J, Zhang Y. Combined Application of Gadoxetic Acid Disodium-Enhanced Magnetic Resonance Imaging (MRI) and Diffusion-Weighted Imaging (DWI) in the Diagnosis of Chronic Liver Disease-Induced Hepatocellular Carcinoma: A Meta-Analysis. PLoS One. 2015;10:e0144247. [PMID: 26629904 DOI: 10.1371/journal.pone.0144247] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
2 Malla RR, Kumari S, Kgk D, Momin S, Nagaraju GP. Nanotheranostics: Their role in hepatocellular carcinoma. Critical Reviews in Oncology/Hematology 2020;151:102968. [DOI: 10.1016/j.critrevonc.2020.102968] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
3 Bittermann T, Goldberg DS, Bauer CM, Khungar V. Characterizing the Risk of False-Positive Hepatocellular Carcinoma in Recipients Transplanted With T2 MELD Exceptions. Transplantation 2017;101:1099-105. [DOI: 10.1097/tp.0000000000001660] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
4 Kim M, Lee S, An C. Problematic lesions in cirrhotic liver mimicking hepatocellular carcinoma. Eur Radiol 2019;29:5101-10. [DOI: 10.1007/s00330-019-06030-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
5 Bashir MR, Horowitz JM, Kamel IR, Arif-Tiwari H, Asrani SK, Chernyak V, Goldstein A, Grajo JR, Hindman NM, Kamaya A, McNamara MM, Porter KK, Solnes LB, Srivastava PK, Zaheer A, Carucci LR; Expert Panel on Gastrointestinal Imaging. ACR Appropriateness Criteria® Chronic Liver Disease. J Am Coll Radiol 2020;17:S70-80. [PMID: 32370979 DOI: 10.1016/j.jacr.2020.01.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Chernyak V, Fowler KJ, Heiken JP, Sirlin CB. Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS): Use of Gadoxetate Disodium and LI-RADS. J Magn Reson Imaging 2019;49:1236-52. [DOI: 10.1002/jmri.26540] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
7 Song X, Shang W, Peng L, Jiang H, Wang K, Fang C, Tian J. Novel GPC3-binding WS2-Ga3+-PEG-peptide nanosheets for in vivo bimodal imaging-guided photothermal therapy. Nanomedicine (Lond) 2018;13:1681-93. [PMID: 30091395 DOI: 10.2217/nnm-2017-0367] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
8 Barr DC, Hussain HK. MR Imaging in Cirrhosis and Hepatocellular Carcinoma. Magnetic Resonance Imaging Clinics of North America 2014;22:315-35. [DOI: 10.1016/j.mric.2014.04.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
9 Chang WC, Chen RC, Chou CT, Lin CY, Yu CY, Liu CH, Chou JM, Hsu HH, Huang GS. Histological grade of hepatocellular carcinoma correlates with arterial enhancement on gadoxetic acid-enhanced and diffusion-weighted MR images. Abdom Imaging 2014;39:1202-12. [PMID: 24869790 DOI: 10.1007/s00261-014-0168-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
10 Jang HY, Choi JI, Lee YJ, Park MY, Yeo DM, Rha SE, Jung ES, You YK, Kim DG, Byun JY. Performance of Gadoxetic Acid-Enhanced Liver Magnetic Resonance Imaging for Predicting Patient Eligibility for Liver Transplantation Based on the Milan Criteria. J Comput Assist Tomogr 2017;41:25-31. [PMID: 27768617 DOI: 10.1097/RCT.0000000000000476] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Yousaf MZ, Yu J, Hou Y, Gao S. Magnetic nanoparticle-based cancer nanodiagnostics. Chinese Phys B 2013;22:058702. [DOI: 10.1088/1674-1056/22/5/058702] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
12 Motosugi U, Bannas P, Sano K, Reeder SB. Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma. J Magn Reson Imaging 2015;41:251-65. [PMID: 25104398 DOI: 10.1002/jmri.24712] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
13 Horowitz JM, Kamel IR, Arif-tiwari H, Asrani SK, Hindman NM, Kaur H, Mcnamara MM, Noto RB, Qayyum A, Lalani T. ACR Appropriateness Criteria ® Chronic Liver Disease. Journal of the American College of Radiology 2017;14:S391-405. [DOI: 10.1016/j.jacr.2017.08.045] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
14 Bashir MR, Hussain HK. Imaging in Patients with Cirrhosis. Radiologic Clinics of North America 2015;53:919-31. [DOI: 10.1016/j.rcl.2015.05.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
15 Fowler KJ, Saad NE, Linehan D. Imaging Approach to Hepatocellular Carcinoma, Cholangiocarcinoma, and Metastatic Colorectal Cancer. Surgical Oncology Clinics of North America 2015;24:19-40. [DOI: 10.1016/j.soc.2014.09.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
16 Song M, Cho HJ, Cho YK, Kim MY, Noh SI, Yang SH. Detecting hepatocellular carcinoma in gadoxetic-acid-enhanced hepatobiliary-phase MR imaging at 3T: comparing high and low flip angle. Jpn J Radiol 2013;31:803-11. [DOI: 10.1007/s11604-013-0255-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
17 Hung S, Jao J, Tzeng J, Huang C, Hwang L, Chen P. Evaluation of Rabbit VX2 Tumor Model Using Magnetic Resonance T1-Mapping and T2-Mapping Techniques at 1.5T. J Med Biol Eng 2018;38:607-17. [DOI: 10.1007/s40846-017-0340-3] [Reference Citation Analysis]
18 Sugimori K, Numata K, Okada M, Nihonmatsu H, Takebayashi S, Maeda S, Nakano M, Tanaka K. Central vascular structures as a characteristic finding of regenerative nodules using hepatobiliary phase gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid-enhanced MRI and arterial dominant phase contrast-enhanced US. J Med Ultrason (2001). 2017;44:89-100. [PMID: 27771842 DOI: 10.1007/s10396-016-0750-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
19 Chen YS, Lim WX, Lin AN, Chen CL, Tsang LL, Yu CY, Hsu HW, Chuang YH, Cheng YF, Ou HY. Clinical Impact of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging on Living Donor Liver Transplant. Transplant Proc 2022:S0041-1345(21)00911-8. [PMID: 35022135 DOI: 10.1016/j.transproceed.2021.09.071] [Reference Citation Analysis]
20 Ba-ssalamah A, Qayyum A, Bastati N, Fakhrai N, Herold CJ, Caseiro Alves F. P4 radiology of hepatobiliary diseases with gadoxetic acid-enhanced MRI as a biomarker. Expert Review of Gastroenterology & Hepatology 2013;8:147-60. [DOI: 10.1586/17474124.2014.876359] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
21 Matsumoto N, Ogawa M, Kaneko M, Kumagawa M, Watanabe Y, Hirayama M, Nakagawara H, Masuzaki R, Kanda T, Moriyama M, Takayama T, Sugitani M. Quantitative Ultrasound Image Analysis Helps in the Differentiation of Hepatocellular Carcinoma (HCC) From Borderline Lesions and Predicting the Histologic Grade of HCC and Microvascular Invasion. J Ultrasound Med 2021;40:689-98. [PMID: 32840896 DOI: 10.1002/jum.15439] [Reference Citation Analysis]
22 Wang JH, Chen TY, Ou HY, Wang CC, Liu YW, Hung CH, Chen CH, Kuo CH, Hu TH, Cheng YF. Clinical Impact of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging on Hepatoma Management: A Prospective Study. Dig Dis Sci. 2016;61:1197-1205. [PMID: 26668057 DOI: 10.1007/s10620-015-3989-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
23 Wu LM, Xu JR, Lu Q, Hua J, Chen J, Hu J. A pooled analysis of diffusion-weighted imaging in the diagnosis of hepatocellular carcinoma in chronic liver diseases. J Gastroenterol Hepatol. 2013;28:227-234. [PMID: 23190006 DOI: 10.1111/jgh.12054] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
24 Shin SK, Kim YS, Choi SJ, Shim YS, Jung DH, Kwon OS, Choi DJ, Kim JH. Characterization of small (≤3 cm) hepatic lesions with atypical enhancement feature and hypointensity in hepatobiliary phase of gadoxetic acid-enhanced MRI in cirrhosis: A STARD-compliant article. Medicine (Baltimore) 2017;96:e7278. [PMID: 28723741 DOI: 10.1097/MD.0000000000007278] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
25 Barr DC, Hussain HK. Magnetic Resonance Imaging in Cirrhosis: What’s New? Topics in Magnetic Resonance Imaging 2014;23:129-49. [DOI: 10.1097/rmr.0000000000000017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Zhao XT, Li WX, Chai WM, Chen KM. Detection of small hepatocellular carcinoma using gadoxetic acid-enhanced MRI: Is the addition of diffusion-weighted MRI at 3.0T beneficial? J Dig Dis. 2014;15:137-145. [PMID: 24354621 DOI: 10.1111/1751-2980.12119] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
27 Suh CH, Kim KW, Kim GY, Shin YM, Kim PN, Park SH. The diagnostic value of Gd-EOB-DTPA-MRI for the diagnosis of focal nodular hyperplasia: A systematic review and meta-analysis. Eur Radiol. 2015;25:950-960. [PMID: 25537979 DOI: 10.1007/s00330-014-3499-9] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 5.8] [Reference Citation Analysis]
28 Jhaveri K, Cleary S, Audet P, Balaa F, Bhayana D, Burak K, Chang S, Dixon E, Haider M, Molinari M, Reinhold C, Sherman M. Consensus Statements From a Multidisciplinary Expert Panel on the Utilization and Application of a Liver-Specific MRI Contrast Agent (Gadoxetic Acid). American Journal of Roentgenology 2015;204:498-509. [DOI: 10.2214/ajr.13.12399] [Cited by in Crossref: 57] [Cited by in F6Publishing: 19] [Article Influence: 8.1] [Reference Citation Analysis]
29 Horowitz JM, Kamel IR, Arif-tiwari H, Asrani SK, Hindman NM, Kaur H, Mcnamara MM, Noto RB, Qayyum A, Lalani T. ACR Appropriateness Criteria ® Chronic Liver Disease. Journal of the American College of Radiology 2017;14:S103-17. [DOI: 10.1016/j.jacr.2017.02.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
30 Kim JH, Yoon JH, Joo I, Lee JM. Evaluation of Primary Liver Cancers Using Hepatocyte-Specific Contrast-Enhanced MRI: Pitfalls and Potential Tips. J Magn Reson Imaging 2021;53:655-75. [PMID: 32700807 DOI: 10.1002/jmri.27213] [Reference Citation Analysis]
31 Wang YC, Chou CT, Lin CP, Chen YL, Chen YF, Chen RC. The value of Gd-EOB-DTPA-enhanced MR imaging in characterizing cirrhotic nodules with atypical enhancement on Gd-DTPA-enhanced MR images. PLoS One 2017;12:e0174594. [PMID: 28355258 DOI: 10.1371/journal.pone.0174594] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
32 Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, Okusaka T, Miyayama S, Tsuchiya K, Ueshima K, Hiraoka A, Ikeda M, Ogasawara S, Yamashita T, Minami T, Yamakado K; Liver Cancer Study Group of Japan. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer 2014;3:458-68. [PMID: 26280007 DOI: 10.1159/000343875] [Cited by in Crossref: 274] [Cited by in F6Publishing: 272] [Article Influence: 39.1] [Reference Citation Analysis]
33 Rhee H, Kim H, Park YN. Clinico-Radio-Pathological and Molecular Features of Hepatocellular Carcinomas with Keratin 19 Expression. Liver Cancer 2020;9:663-81. [PMID: 33442539 DOI: 10.1159/000510522] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
34 Li B, Li B, Guo T, Sun Z, Li X, Li X, Chen L, Zhao J, Mao Y. Artificial neural network models for early diagnosis of hepatocellular carcinoma using serum levels of α-fetoprotein, α-fetoprotein-L3, des-γ-carboxy prothrombin, and Golgi protein 73. Oncotarget 2017;8:80521-30. [PMID: 29113322 DOI: 10.18632/oncotarget.19298] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
35 Lan H, Lin G, Zhong W. A meta-analysis of the added value of diffusion weighted imaging in combination with contrast-enhanced magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma lesser or equal to 2 cm. Oncol Lett 2020;20:2739-48. [PMID: 32782590 DOI: 10.3892/ol.2020.11805] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
36 Willatt J, Ruma JA, Azar SF, Dasika NL, Syed F. Imaging of hepatocellular carcinoma and image guided therapies - how we do it. Cancer Imaging 2017;17:9. [PMID: 28259177 DOI: 10.1186/s40644-017-0110-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
37 Choi MH, Choi JI, Lee YJ, Park MY, Rha SE, Lall C. MRI of Small Hepatocellular Carcinoma: Typical Features Are Less Frequent Below a Size Cutoff of 1.5 cm. AJR Am J Roentgenol 2017;208:544-51. [PMID: 28026208 DOI: 10.2214/AJR.16.16414] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
38 Chan MV, Huo YR, Trieu N, Mitchelle A, George J, He E, Lee AU, Chang J, Yang J. Noncontrast MRI for Hepatocellular Carcinoma Detection: A Systematic Review and Meta-analysis - A Potential Surveillance Tool? Clin Gastroenterol Hepatol 2021:S1542-3565(21)00215-9. [PMID: 33662596 DOI: 10.1016/j.cgh.2021.02.036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
39 Thian YL, Riddell AM, Koh DM. Liver-specific agents for contrast-enhanced MRI: role in oncological imaging. Cancer Imaging. 2013;13:567-579. [PMID: 24434892 DOI: 10.1102/1470-7330.2013.0050] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
40 Erra P, Puglia M, Ragozzino A, Maurea S, Liuzzi R, Sabino G, Barbuto L, Cuocolo A, Imbriaco M. Appearance of hepatocellular carcinoma on gadoxetic acid-enhanced hepato-biliary phase MR imaging: a systematic review. Radiol Med. 2015;120:1002-1011. [PMID: 25900253 DOI: 10.1007/s11547-015-0539-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
41 Choi BI, Lee JM, Kim TK, Dioguardi Burgio M, Vilgrain V. Diagnosing Borderline Hepatic Nodules in Hepatocarcinogenesis: Imaging Performance. AJR Am J Roentgenol. 2015;205:10-21. [PMID: 26102378 DOI: 10.2214/ajr.14.12655] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 3.9] [Reference Citation Analysis]
42 Ramalho M, Matos AP, AlObaidy M, Velloni F, Altun E, Semelka RC. Magnetic resonance imaging of the cirrhotic liver: diagnosis of hepatocellular carcinoma and evaluation of response to treatment - Part 1. Radiol Bras. 2017;50:38-47. [PMID: 28298731 DOI: 10.1590/0100-3984.2015.0132] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
43 Kim JH, Joo I, Lee JM. Atypical Appearance of Hepatocellular Carcinoma and Its Mimickers: How to Solve Challenging Cases Using Gadoxetic Acid-Enhanced Liver Magnetic Resonance Imaging. Korean J Radiol 2019;20:1019-41. [PMID: 31270973 DOI: 10.3348/kjr.2018.0636] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
44 Pang EH, Harris AC, Chang SD. Approach to the Solitary Liver Lesion: Imaging and When to Biopsy. Can Assoc Radiol J 2016;67:130-48. [DOI: 10.1016/j.carj.2015.07.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
45 Scali EP, Walshe T, Tiwari HA, Harris AC, Chang SD. A Pictorial Review of Hepatobiliary Magnetic Resonance Imaging With Hepatocyte-Specific Contrast Agents: Uses, Findings, and Pitfalls of Gadoxetate Disodium and Gadobenate Dimeglumine. Can Assoc Radiol J 2017;68:293-307. [PMID: 28583364 DOI: 10.1016/j.carj.2016.10.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
46 Sofue K, Sirlin CB, Allen BC, Nelson RC, Berg CL, Bashir MR. How reader perception of capsule affects interpretation of washout in hypervascular liver nodules in patients at risk for hepatocellular carcinoma. J Magn Reson Imaging 2016;43:1337-45. [PMID: 26559157 DOI: 10.1002/jmri.25094] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
47 Pan J, Li W, Gu L, Liu C, Zhang K, Hong G. Performance of adding hepatobiliary phase image in magnetic resonance imaging for detection of hepatocellular carcinoma: a meta-analysis. Eur Radiol 2022. [PMID: 35579711 DOI: 10.1007/s00330-022-08826-z] [Reference Citation Analysis]
48 Morisaka H, Motosugi U, Ichikawa S, Ichikawa T, Kondo T, Onishi H. Uptake of gadoxetic acid in hepatobiliary phase magnetic resonance imaging and transporter expression in hypovascular hepatocellular nodules. Eur J Radiol 2021;138:109669. [PMID: 33770738 DOI: 10.1016/j.ejrad.2021.109669] [Reference Citation Analysis]
49 Wu LM, Xu JR, Gu HY, Hua J, Chen J, Zhu J, Zhang W, Hu J. Is liver-specific gadoxetic acid-enhanced magnetic resonance imaging a reliable tool for detection of hepatocellular carcinoma in patients with chronic liver disease? Dig Dis Sci. 2013;58:3313-3325. [PMID: 23884757 DOI: 10.1007/s10620-013-2790-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]